Brief: Cstone Pharmaceuticals Says China NMPA Approved New Drug Application Of Tibsovo For Treatment Of Acute Myeloid Leukemia
09/02/2022 06:30
Feb 9 (Reuters) - CStone Pharmaceuticals:
* CHINA NMPA APPROVED NEW DRUG APPLICATION OF TIBSOVO FOR
TREATMENT OF ACUTE MYELOID LEUKEMIA
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026